|
시장보고서
상품코드
1388197
통풍 치료제 시장 점유율, 규모, 동향, 산업 분석 리포트 : 약제 클래스별, 병상별, 지역별, 부문별 예측(2023-2032년)Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents); By Disease Condition; By Region; Segment Forecast, 2023 - 2032 |
||||||
Polaris market research의 최신 조사에 따르면 세계의 통풍 치료제 시장 규모는 2032년까지 60억 4,000만 달러에 달할 전망입니다. 이 리포트는 현재 시장 역학에 관한 상세 인사이트와 향후 시장 성장에 관한 분석을 제공하고 있습니다.
생물학적 제제는 재생치료에 초점을 맞춘 연구개발이 증가하면서 수용이 증가하고 있습니다. 이러한 혁신적인 치료법은 통풍의 증상과 근본 원인을 해결하는 데 큰 잠재력을 보여주고 있습니다. 또한 영상 진단 기법의 눈부신 발전으로 통풍을 효과적으로 진단하고 모니터링할 수 있는 능력이 향상되고 있습니다.
또한 통풍이라는 질병과 그 위험 요인에 대한 이해가 높아지면서 의료 전문가와 환자들의 인식도 높아졌습니다. 통풍은 주로 혈중 요산 수치가 높은 40세 이상 남성에게 발병합니다. 남성은 여성에 비해 통풍에 걸리기 쉽습니다. 과도한 요산은 바늘 모양의 결정체를 형성하여 관절통, 염증 및 통증을 유발합니다.
이러한 복합적인 요인으로 인해 효과적인 통풍 치료제에 대한 수요가 증가하고 있습니다. 제약회사와 연구자들은 통풍의 증상과 장기적인 관리에 구상하기 위해 새롭고 개선된 치료법을 개발하기 위해 적극적으로 노력하고 있습니다. 그 목적은 환자에게 통증을 완화하고 염증을 억제하며 통풍 발작의 재발을 예방하는 표적 치료법을 제공하는 것입니다.
통풍은 라이프스타일의 변화와 식습관 요인으로 인해 세계에서 환자 수가 증가하고 있습니다. 시장은 새로운 약물 처방 및 조합을 포함한 치료 옵션의 발전을 목격하고 있으며, 이는 효능과 편의성을 향상시키고 있습니다.
또한 환자 개개인의 특성에 따라 치료법을 조정하는 개인 맞춤형 의료 접근법도 확산되고 있습니다. 인식과 진단율 증가, 기술 발전, 신흥 시장에서의 확대는 시장 성장에 더욱 기여하고 있습니다. 또한 통풍 치료제 연구개발은 업계 주요 기업간의 제휴 및 협력 관계를 통해 촉진되고 있습니다.
통풍치료제 시장 보고서 하이라이트
비스테로이드성 항염증제(NSAIDs) 분야가 가장 높은 점유율로 시장을 장악하고 있습니다. 비스테로이드성 항염증제(NSAIDs)는 널리 이용 가능하고, 비용 효율적이며, 심한 통풍 발작에 효과적이기 때문에 류마티스 및 비류마티스 질환에서 염증과 통증을 완화하는 1차 선택 약품으로 선호되고 있습니다.
만성 부문은 시장에서 가장 큰 매출 점유율을 차지할 것으로 예상됩니다. 이 부문의 성장은 다양한 요산강하제의 도입과 새로운 치료제 시장 진입 가능성에 의해 촉진되고 있습니다.
북미가 시장을 독점하고 있으며, 예측 기간 중에도 그 우위를 유지할 것으로 보입니다. 통풍은 북미에서 많은 사람들에게 영향을 미치고 있으며, 미국에서만 830만 명이 통풍을 앓고 있는 것으로 추정되며, 유병률은 1-4%에 달할 전망입니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 통풍 치료제 시장 인사이트
- 통풍 치료제 시장 - 업계 스냅숏
- 통풍 치료제 시장 역학
- 촉진요인과 기회
- 전 세계에서 통풍의 유병률이 증가
- 지속적 연구개발 활동
- 억제요인과 과제
- 치료비
- 촉진요인과 기회
- PESTLE 분석
- 통풍 치료제 업계의 동향
- 밸류체인 분석
- COVID-19 감염증의 영향 분석
제5장 세계의 통풍 치료제 시장, 약제 클래스별
- 주요 조사 결과
- 서론
- 비스테로이드성 항염증약(NSAIDs)
- 코르티코스테로이드
- 콜히친
- 요산 강하제
제6장 세계의 통풍 치료제 시장, 병상별
- 주요 조사 결과
- 서론
- 급성
- 만성
제7장 세계의 통풍 치료제 시장, 지역별
- 주요 조사 결과
- 서론
- 통풍 치료제 시장 평가, 지역별, 2019-2032년
- 통풍 치료제 시장 - 북미
- 북미 : 통풍 치료제 시장, 병상별, 2019-2032년
- 북미 : 통풍 치료제 시장, 약제 클래스별, 2019-2032년
- 통풍 치료제 시장 - 미국
- 통풍 치료제 시장 - 캐나다
- 통풍 치료제 시장 - 유럽
- 유럽 : 통풍 치료제 시장, 병상별, 2019-2032년
- 유럽 : 통풍 치료제 시장, 약제 클래스별, 2019-2032년
- 통풍 치료제 시장 - 영국
- 통풍 치료제 시장 - 프랑스
- 통풍 치료제 시장 - 독일
- 통풍 치료제 시장 - 이탈리아
- 통풍 치료제 시장 - 스페인
- 통풍 치료제 시장 - 네덜란드
- 통풍 치료제 시장 - 러시아
- 통풍 치료제 시장 - 아시아태평양
- 아시아태평양 : 통풍 치료제 시장, 병상별, 2019-2032년
- 아시아태평양 : 통풍 치료제 시장, 약제 클래스별, 2019-2032년
- 통풍 치료제 시장 - 중국
- 통풍 치료제 시장 - 인도
- 통풍 치료제 시장 - 말레이시아
- 통풍 치료제 시장 - 일본
- 통풍 치료제 시장 - 인도네시아
- 통풍 치료제 시장 - 한국
- 통풍 치료제 시장 - 중동 및 아프리카
- 중동 및 아프리카 : 통풍 치료제 시장, 병상별, 2019-2032년
- 중동 및 아프리카 : 통풍 치료제 시장, 약제 클래스별, 2019-2032년
- 통풍 치료제 시장 - 사우디아라비아
- 통풍 치료제 시장 - 아랍에미리트
- 통풍 치료제 시장 - 이스라엘
- 통풍 치료제 시장 - 남아프리카
- 통풍 치료제 시장 - 라틴아메리카
- 라틴아메리카 : 통풍 치료제 시장, 병상별, 2019-2032년
- 라틴아메리카 : 통풍 치료제 시장, 약제 클래스별, 2019-2032년
- 통풍 치료제 시장 - 멕시코
- 통풍 치료제 시장 - 브라질
- 통풍 치료제 시장 - 아르헨티나
제8장 경쟁 구도
- 확장과 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제9장 기업 개요
- Ablynx
- Antares Pharma
- Astellas Pharma
- AstraZeneca
- Boehringer Ingelheim
- CymaBay Therapeutics
- Eisai
- Eli Lilly
- GlaxoSmithKline
- Horizon Pharma
- JW Pharmaceutical
- LG Life Sciences
- Merck
- Novartis
- Novo Nordisk
- Regeneron Pharmaceuticals
- Sandoz(a subsidiary of Novartis)
- Sanofi
- Takeda Pharmaceuticals
- Teijin Pharma
- Vertex Pharmaceuticals
The global gout therapeutics market size is expected to reach USD 6.04 billion by 2032, according to a new study by Polaris market research. The report "Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents); By Disease Condition; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Biologics has a rising acceptance and increased research and development focused on regeneration therapies. These innovative treatment approaches show great promise in addressing gout's symptoms and underlying causes. Additionally, there have been significant advancements in imaging modalities, which have enhanced the ability to diagnose and monitor gout effectively.
Furthermore, a greater understanding of the disease and its risk factors leads to increased awareness among healthcare professionals and patients. Gout primarily affects men over 40 with high uric acid levels in their blood. Males are more susceptible to developing gout compared to females. Excessive uric acid leads to the formation of needle-like crystals, which can result in joint pain, inflammation, and soreness.
These combined factors have propelled the demand for effective gout therapeutics. Pharmaceutical companies and researchers are actively working to develop new and improved treatment options to address the symptoms and long-term management of gout. The aim is to provide patients with targeted therapies that alleviate pain, reduce inflammation, and prevent recurrent gout attacks.
Gout is growing globally due to lifestyle changes and dietary factors, expanding the patient pool. The market is witnessing advancements in treatment options, including new drug formulations and combinations, offering improved efficacy and convenience.
Additionally, personalized medicine approaches are gaining traction, tailoring treatments based on individual patient characteristics. Rising awareness and diagnosis rates, technological advancements, and expansion in emerging markets further contribute to the market's growth. Collaborations and partnerships among key industry players also facilitate research and development efforts in gout therapeutics.
Gout Therapeutics Market Report Highlights
NSAIDs segment dominated the market with highest share. Due to their widespread availability, cost-effectiveness, and efficacy during severe gout attacks, NSAIDs are the preferred first-line treatment for reducing inflammation and pain in rheumatic and non-rheumatic diseases.
Chronic segment anticipated to hold the largest revenue share of the market. The growth of this segment is fueled by the introduction of various urate-lowering drugs and the potential for new treatments to enter the market.
North America dominated the market and willing to maintain its dominance over the forecast period. Gout affects many people in North America, with an estimated 8.3 million individuals affected in the United States alone and a prevalence rate ranging from 1% to 4%.
The global key market players include: Ablynx, Antares Pharma, CymaBay Therapeutics, Astellas Pharma, AstraZeneca, Horizon Pharma, Boehringer Ingelheim, Merck, Eisai, Regeneron Pharmaceuticals, Eli Lilly and others.
Polaris market research has segmented the gout therapeutics market report based on drug class, disease condition, and region:
Gout Therapeutics, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)
- Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
- Corticosteroids
- Colchicine
- Urate Lowering Agents
Gout Therapeutics, Disease Condition Outlook (Revenue - USD Billion, 2019 - 2032)
- Acute
- Chronic
Gout Therapeutics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Gout Therapeutics Market Insights
- 4.1. Gout Therapeutics Market - Industry Snapshot
- 4.2. Gout Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing prevalence of gout worldwide
- 4.2.1.2. Continuous research and development activities
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Cost of treatment
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. Gout Therapeutics Industry trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Gout Therapeutics Market, by Drug Class
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Gout Therapeutics, by Drug Class, 2019-2032 (USD Billion)
- 5.3. Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
- 5.3.1. Global Gout Therapeutics Market, by Non-steroidal Anti-Inflammatory Drugs (NSAIDs) by Region, 2019-2032 (USD Billion)
- 5.4. Corticosteroids
- 5.4.1. Global Gout Therapeutics Market, by Corticosteroids, by Region, 2019-2032 (USD Billion)
- 5.5. Colchicine
- 5.5.1. Global Gout Therapeutics Market, by Colchicine, by Region, 2019-2032 (USD Billion)
- 5.6. Urate Lowering Agents
- 5.6.1. Global Gout Therapeutics Market, by Urate Lowering Agents, by Region, 2019-2032 (USD Billion)
6. Global Gout Therapeutics Market, by Disease Condition
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 6.3. Acute
- 6.3.1. Global Gout Therapeutics Market, by Acute, by Region, 2019-2032 (USD Billion)
- 6.4. Chronic
- 6.4.1. Global Gout Therapeutics Market, by Chronic, by Region, 2019-2032 (USD Billion)
7. Global Gout Therapeutics Market, by Geography
- 7.1. Key findings
- 7.2. Introduction
- 7.2.1. Gout Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
- 7.3. Gout Therapeutics Market - North America
- 7.3.1. North America: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.3.2. North America: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.3.3. Gout Therapeutics Market - U.S.
- 7.3.3.1. U.S.: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.3.3.2. U.S.: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.3.4. Gout Therapeutics Market - Canada
- 7.3.4.1. Canada: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.3.4.2. Canada: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4. Gout Therapeutics Market - Europe
- 7.4.1. Europe: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.4.2. Europe: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.3. Gout Therapeutics Market - UK
- 7.4.3.1. UK: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.4.3.2. UK: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.4. Gout Therapeutics Market - France
- 7.4.4.1. France: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.4.4.2. France: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.5. Gout Therapeutics Market - Germany
- 7.4.5.1. Germany: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.4.5.2. Germany: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.6. Gout Therapeutics Market - Italy
- 7.4.6.1. Italy: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.4.6.2. Italy: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.7. Gout Therapeutics Market - Spain
- 7.4.7.1. Spain: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.4.7.2. Spain: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.8. Gout Therapeutics Market - Netherlands
- 7.4.8.1. Netherlands: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.4.8.2. Netherlands: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.9. Gout Therapeutics Market - Russia
- 7.4.9.1. Russia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.4.9.2. Russia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5. Gout Therapeutics Market - Asia Pacific
- 7.5.1. Asia Pacific: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.5.2. Asia Pacific: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.3. Gout Therapeutics Market - China
- 7.5.3.1. China: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.5.3.2. China: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.4. Gout Therapeutics Market - India
- 7.5.4.1. India: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.5.4.2. India: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.5. Gout Therapeutics Market - Malaysia
- 7.5.5.1. Malaysia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.5.5.2. Malaysia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.6. Gout Therapeutics Market - Japan
- 7.5.6.1. Japan: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.5.6.2. Japan: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.7. Gout Therapeutics Market - Indonesia
- 7.5.7.1. Indonesia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.5.7.2. Indonesia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.8. Gout Therapeutics Market - South Korea
- 7.5.8.1. South Korea: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.5.8.2. South Korea: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.6. Gout Therapeutics Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.6.2. Middle East & Africa: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.6.3. Gout Therapeutics Market - Saudi Arabia
- 7.6.3.1. Saudi Arabia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.6.3.2. Saudi Arabia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.6.4. Gout Therapeutics Market - UAE
- 7.6.4.1. UAE: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.6.4.2. UAE: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.6.5. Gout Therapeutics Market - Israel
- 7.6.5.1. Israel: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.6.5.2. Israel: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.6.6. Gout Therapeutics Market - South Africa
- 7.6.6.1. South Africa: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.6.6.2. South Africa: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.7. Gout Therapeutics Market - Latin America
- 7.7.1. Latin America: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.7.2. Latin America: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.7.3. Gout Therapeutics Market - Mexico
- 7.7.3.1. Mexico: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.7.3.2. Mexico: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.7.4. Gout Therapeutics Market - Brazil
- 7.7.4.1. Brazil: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.7.4.2. Brazil: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.7.5. Gout Therapeutics Market - Argentina
- 7.7.5.1. Argentina: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.7.5.2. Argentina: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
- 9.1. Ablynx
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. Antares Pharma
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Astellas Pharma
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. AstraZeneca
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. Boehringer Ingelheim
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. CymaBay Therapeutics
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. Eisai
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Eli Lilly
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. GlaxoSmithKline
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. Horizon Pharma
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
- 9.11. JW Pharmaceutical
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development
- 9.12. LG Life Sciences
- 9.12.1. Company Overview
- 9.12.2. Financial Performance
- 9.12.3. Product Benchmarking
- 9.12.4. Recent Development
- 9.13. Merck
- 9.13.1. Company Overview
- 9.13.2. Financial Performance
- 9.13.3. Product Benchmarking
- 9.13.4. Recent Development
- 9.14. Novartis
- 9.14.1. Company Overview
- 9.14.2. Financial Performance
- 9.14.3. Product Benchmarking
- 9.14.4. Recent Development
- 9.15. Novo Nordisk
- 9.15.1. Company Overview
- 9.15.2. Financial Performance
- 9.15.3. Product Benchmarking
- 9.15.4. Recent Development
- 9.16. Regeneron Pharmaceuticals
- 9.16.1. Company Overview
- 9.16.2. Financial Performance
- 9.16.3. Product Benchmarking
- 9.16.4. Recent Development
- 9.17. Sandoz (a subsidiary of Novartis)
- 9.17.1. Company Overview
- 9.17.2. Financial Performance
- 9.17.3. Product Benchmarking
- 9.17.4. Recent Development
- 9.18. Sanofi
- 9.18.1. Company Overview
- 9.18.2. Financial Performance
- 9.18.3. Product Benchmarking
- 9.18.4. Recent Development
- 9.19. Takeda Pharmaceuticals
- 9.19.1. Company Overview
- 9.19.2. Financial Performance
- 9.19.3. Product Benchmarking
- 9.19.4. Recent Development
- 9.20. Teijin Pharma
- 9.20.1. Company Overview
- 9.20.2. Financial Performance
- 9.20.3. Product Benchmarking
- 9.20.4. Recent Development
- 9.21. Vertex Pharmaceuticals
- 9.21.1. Company Overview
- 9.21.2. Financial Performance
- 9.21.3. Product Benchmarking
- 9.21.4. Recent Development
